five years result of photodynamic therapy with ranibizumab for polypoidal choroidal vasculopathy

five years result of photodynamic therapy with ranibizumab for polypoidal choroidal vasculopathy - 5 years result of PDT with IVR for PCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029429

Enrollment

Registered

2017-10-05

Start date

2009-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: treatment-naive polypoidal choroidal vasculopathy

Exclusion criteria

Exclusion criteria: (1) any treatment for PCV prior to PDT, including laser photocoagulation, transpupillary thermotherapy,or radiotherapy (2) other concomitant ocular diseases, such as diabetic retinopathy, high myopia, vein or artery occlusion, or epiretinal membrane (3) any systemic contraindications to verteporfin or angiographic dyes (4) idiopathic or secondary choroidal neovascularization; (5) RPE tears or ripping.

Design outcomes

Primary

Measure	Time frame
The change of best-corrected visual acuity at 1,2,3,4 and 5 years after treatment	—

Secondary

Measure	Time frame
The change of central retinal thickness 1,2,3,4 and 5 years after treatment number of treatments local and systemic complications	—

Countries

Japan

Contacts

Public ContactHarumi Wakiyama

The Japanese Red Cross Nagasaki Genbaku Hospital Ophthalmology

wakiyama@nagasaki-med.jrc.or.jp095-847-1511

Outcome results